These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36917920)

  • 1. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
    Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
    J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
    Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
    Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hospitalization due to infection in rituximab-treated MS patients.
    Karlowicz JR; Klakegg M; Aarseth JH; Bø L; Myhr KM; Torgauten HM; Torkildsen Ø; Wergeland S
    Mult Scler Relat Disord; 2023 Mar; 71():104556. PubMed ID: 36842313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
    Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
    J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.
    Langer-Gould A; Li BH; Smith JB; Xu S
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200211. PubMed ID: 38507657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
    Barmettler S; Ong MS; Farmer JR; Choi H; Walter J
    JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
    Kim SH; Park NY; Kim KH; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35853752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
    Sacco KA; Abraham RS
    Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
    Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
    Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
    Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
    Filanovsky K; Miller EB; Sigler E; Berrebi A; Shvidel L
    Recent Pat Anticancer Drug Discov; 2016; 11(2):228-35. PubMed ID: 26825174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
    Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
    Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
    Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
    Kridin K; Ahmed AR
    Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
    Tallantyre EC; Whittam DH; Jolles S; Paling D; Constantinesecu C; Robertson NP; Jacob A
    J Neurol; 2018 May; 265(5):1115-1122. PubMed ID: 29511864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
    Podestà MA; Mescia F; Ricchiuto A; Smith R; Tedesco M; Cassia MA; Holle J; Sinico RA; Bruchfeld A; Gunnarsson I; Ohlsson S; Baslund B; Hruskova Z; Tesar V; Sabiu G; Gallieni M; Cid MC; Vaglio A; Harper L; Cozzolino M; Scolari F; Jayne D; Alberici F
    Rheumatology (Oxford); 2023 Aug; 62(8):2850-2854. PubMed ID: 36562566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.